KNSA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KNSA exhibits strong deterministic health with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.02), yet it faces a severe valuation disconnect. The current price of $47.08 trades at a massive premium to its Graham Number ($11.20) and Intrinsic Value ($5.25), suggesting the market is pricing in aggressive future growth. While revenue growth is impressive at 65% YoY, the company has missed earnings estimates in 4 consecutive quarters with an average surprise of -35.29%. This fundamental instability, coupled with heavy C-suite insider selling and a bearish technical trend, offsets the strong financial health.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
KNSA vs LLY: Head-to-Head Comparison
This page compares Kiniksa Pharmaceuticals International, plc (KNSA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.